News coverage of Gilead Sciences has skyrocketed this year driven by interest in the company’s antiviral drug remdesivir, which is aimed at treating Covid-19.
To appreciate the magnitude of the increase I pulled data from Bloomberg that shows Gilead garnering a daily average of 211 news articles so far this year.
That’s the largest for any of the 60 members of the S&P 500 Health Care Index and a four-fold increase from last year. It’s significantly higher than Johnson & Johnson, the No. 2 company on the list.
The increase is also remarkable because the comparison underscores how news coverage of most companies tends to be fairly stable year in and year out.
Note: the data is complied from Bloomberg’s professional terminal, which aggregates 175,000 news sources.